Full Breakdown
BASF and Evonik Enter Exploratory Talks Amid Industry Restructuring
By Drooid · · How we work
Core Event: Potential Takeover Discussions
- On 25 September, BASF confirmed exploratory talks with Evonik and its largest shareholder, the RAG-Stiftung, about a possible takeover. BASF said the discussions are preliminary and non-binding. Evonik acknowledged receipt of the approach but noted no formal talks are underway and limited comment to legal obligations.
Background & Context
- The European chemicals sector faces high energy costs, weak demand and competition from Chinese producers. BASF’s CEO Markus Kamieth described the environment as the toughest in 25 years, prompting a search for acquisitions to strengthen its specialty-chemicals portfolio.
- Evonik is executing a “Tailor Made” restructuring programme to address a structural crisis, including job cuts, site closures and divestments.
Key Figures & Groups
- Markus Kamieth — CEO, BASF.
- Claus Rettig — Interim CEO of Evonik (appointed in August).
- RAG-Stiftung — Holds roughly 43 % of Evonik and is part of the discussions.
Timeline
- August – Claus Rettig named interim CEO.
- 2027-2029 – Second phase of Evonik’s restructuring.
- Mid-2027 – Planned closure of the Hamburg site (? 50 employees).
- April 2027 – Planned closure of the Bitterfeld site (? 40 employees).
- 25 September – BASF confirms exploratory talks.
Data & Statistics
- Evonik plans to cut 3,200 jobs, about two-thirds in Germany.
- Investment commitments: €93 million for a GMP drug-product facility in Vancouver (up to €42 million from Canada’s Strategic Response Fund) and €80 million to expand fermentation capacity for APIs in Slovakia.
- Overlap between the firms includes plastics (polyamides, high-performance polymers), specialty chemicals (coatings, personal-care ingredients, pharmaceutical excipients) and nutrition ingredients (amino acids, vitamins).
Official Statements & Responses
- BASF stressed the talks are exploratory, with no decision made, and that it continuously evaluates acquisitions fitting its strategic goals.
- Evonik confirmed receipt of a non-binding approach, reiterated no formal negotiations, and limited further comment to legal obligations.
- RAG-Stiftung confirmed its involvement and its 43 % ownership stake.
Why It Matters / Impact
- A combined BASF-Evonik entity would merge BASF’s broad portfolio with Evonik’s specialty businesses, creating a larger platform across downstream markets such as high-performance polymers, nutrition ingredients and pharmaceutical materials.
- The merger could improve capacity utilisation and strengthen Europe’s position against Chinese chemical producers.
- Ongoing restructuring at Evonik—including job cuts and site closures—may be accelerated depending on the talks’ outcome, affecting regional employment and supply chains in Germany.
What’s Next
- Both companies say discussions are at an early stage. Progress would require further due-diligence, shareholder approval from RAG-Stiftung and European regulatory review. No specific future dates have been announced.